CNSP Stock Overview A clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
CNS Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for CNS Pharmaceuticals Historical stock prices Current Share Price US$0.11 52 Week High US$65.50 52 Week Low US$0.096 Beta 1.06 1 Month Change -1.29% 3 Month Change -18.45% 1 Year Change -99.82% 3 Year Change -99.99% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement Nov 02 CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million. Oct 24
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement Sep 12 CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated Jul 30
CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million. Jul 27
The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024 Jul 25 See more updates
CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement Nov 02 CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million. Oct 24
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement Sep 12 CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated Jul 30
CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million. Jul 27
The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024 Jul 25 CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million. Jul 05
CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million. Jul 04
CNS Pharmaceuticals, Inc. announced a financing transaction CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.
New major risk - Share price stability Jun 04
CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024 Mar 29
CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Feb 28
CNS Pharmaceuticals Provides Non-Compliance Update Feb 22 CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering. Dec 09
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy Nov 23
New major risk - Negative shareholders equity Nov 17
CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland Oct 12
Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm) Sep 09
CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1) Aug 19
CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023 Aug 16 CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023
CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme Aug 04
Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors May 09
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Feb 08
CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland Jan 13
Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors Jan 04
CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM) Dec 09 CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering. Dec 02
Insufficient new directors Nov 16
CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Nov 03
CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Sep 29
CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer Aug 16
CNS Pharmaceuticals reports Q2 results Aug 15
CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022 Jun 29
CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM Jun 24
CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Jun 09
Price target increased to US$10.00 May 26
Insufficient new directors Apr 27
CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme Apr 06
CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding Jan 07
Insufficient new directors Dec 05
Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation Dec 04
CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme Dec 03
FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme Jun 30
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin May 21
CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021 Feb 27
WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials Feb 25
WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study Feb 19
New 90-day high: US$3.50 Feb 05
CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application Dec 30
CNS Pharmaceuticals sinks after pricing equity offering of $10M Dec 23
CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin Dec 19
New 90-day high: US$2.89 Dec 19 Shareholder Returns CNSP US Pharmaceuticals US Market 7D 4.5% 2.9% 2.8% 1Y -99.8% 8.8% 24.5%
See full shareholder returns
Return vs Market: CNSP underperformed the US Market which returned 24.5% over the past year.
Price Volatility Is CNSP's price volatile compared to industry and market? CNSP volatility CNSP Average Weekly Movement 13.3% Pharmaceuticals Industry Average Movement 10.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CNSP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNSP's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Show more CNS Pharmaceuticals, Inc. Fundamentals Summary How do CNS Pharmaceuticals's earnings and revenue compare to its market cap? CNSP fundamental statistics Market cap US$6.27m Earnings (TTM ) -US$17.06m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CNSP income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$17.06m Earnings -US$17.06m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 00:25 End of Day Share Price 2024/12/26 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CNS Pharmaceuticals, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Cross Alliance Global Partners Bruce Jackson Benchmark Company Robert LeBoyer Ladenburg Thalmann & Company
Show 1 more analysts 
